J&J's EU OK for Remicade may propel it towards domination of paediatric ulcerative colitis
This article was originally published in Scrip
Executive Summary
Janssen Biologic's anti TNF Remicade (infliximab) looks set to win EU approval for paediatric ulcerative colitis after the EMA's scientific committee, the CHMP, issued a positive opinion for the indication on 19 January.